Shenzhen Geno-immune Medical Institute

This study tests a new treatment called multi-CAR T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard care. The therapy uses the patient's own immune cells, modified to target several markers on leukemia cells. The goal is t…

This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with certain brain tumors, including glioblastoma. The therapy uses a patient's own immune cells, modified to target a protein called DLL3 found on tumor cells. The goal is to see if it is safe and can shri…

This early-stage trial tests a gene therapy for X-linked severe combined immunodeficiency (SCID-X1), a rare genetic disorder that leaves babies without a working immune system. The treatment uses a modified virus to deliver a corrected gene directly into the bloodstream. The goal…

This study tests a new treatment for people with advanced melanoma that has not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if this approach i…

This early-phase study tests a universal (off-the-shelf) CAR-T cell therapy for people with multiple myeloma whose cancer is in remission but who have limited treatment options. About 20 participants will receive the therapy to see if it is safe and can control the disease. The s…

This study tests a new treatment for people with a rare, aggressive brain cancer called diffuse midline glioma or DIPG. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific mutation (H3K27M). The g…

This study is testing a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses a mix of specially engineered immune cells designed to attack cancer cells in multiple ways. The goal is to see if this combinat…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This study tests a new treatment that uses a patient's own immune cells, specially engineered to target cancer. The goal is to see if these cells are safe and can shrink tumors. About 100 people with different types of cancer will take part. The treatment is still experimental an…

This study tests a new treatment called 4SCAR-T cells for people with advanced bladder cancer that has spread and has no other treatment options. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The trial aims to see if…

This trial tests a gene therapy for Chronic Granulomatous Disease (CGD), a rare immune disorder that causes severe infections. The therapy uses a modified virus to deliver a working copy of the faulty gene into the patient's bone marrow cells. The goal is to restore immune functi…

This study tests a new treatment for people with solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many tumor cells. The goal is to control the disease and unde…

This early-stage trial tests a gene therapy for hemophilia B, a bleeding disorder. Doctors take a patient's own stem cells, add a working gene for clotting factor IX, and put them back. The goal is to see if it's safe and helps the body make its own clotting factor, reducing the …